161 related articles for article (PubMed ID: 26661829)
21. INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.
Hu JL; Hu XL; Han Q; Guo AY; Wang CJ; Wen YY; Cang SD
Gene Ther; 2017 Jul; 24(7):392-398. PubMed ID: 28436941
[TBL] [Abstract][Full Text] [Related]
22. Exosomes as mediators of platinum resistance in ovarian cancer.
Crow J; Atay S; Banskota S; Artale B; Schmitt S; Godwin AK
Oncotarget; 2017 Feb; 8(7):11917-11936. PubMed ID: 28060758
[TBL] [Abstract][Full Text] [Related]
23. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
24. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
25. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.
Marchini S; Fruscio R; Clivio L; Beltrame L; Porcu L; Fuso Nerini I; Cavalieri D; Chiorino G; Cattoretti G; Mangioni C; Milani R; Torri V; Romualdi C; Zambelli A; Romano M; Signorelli M; di Giandomenico S; D'Incalci M
Eur J Cancer; 2013 Jan; 49(2):520-30. PubMed ID: 22897840
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Lee YK; Park NH; Lee H
Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
[TBL] [Abstract][Full Text] [Related]
28. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
[TBL] [Abstract][Full Text] [Related]
29. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
[TBL] [Abstract][Full Text] [Related]
30. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
Xia B; Yang S; Liu T; Lou G
Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA‑455 inhibits cell proliferation and invasion of epithelial ovarian cancer by directly targeting Notch1.
Xu L; Li H; Su L; Lu Q; Liu Z
Mol Med Rep; 2017 Dec; 16(6):9777-9785. PubMed ID: 29039517
[TBL] [Abstract][Full Text] [Related]
32. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
[TBL] [Abstract][Full Text] [Related]
34. [Specific folic-acid targeted photosensitizer. The first step toward intraperitoneal photodynamic therapy for epithelial ovarian cancer].
Azaïs H; Frochot C; Grabarz A; Khodja Bach S; Colombeau L; Delhem N; Mordon S; Collinet P
Gynecol Obstet Fertil Senol; 2017 Apr; 45(4):190-196. PubMed ID: 28359805
[TBL] [Abstract][Full Text] [Related]
35. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
Heo EJ; Cho YJ; Cho WC; Hong JE; Jeon HK; Oh DY; Choi YL; Song SY; Choi JJ; Bae DS; Lee YY; Choi CH; Kim TJ; Park WY; Kim BG; Lee JW
Cancer Res Treat; 2017 Oct; 49(4):915-926. PubMed ID: 28052650
[TBL] [Abstract][Full Text] [Related]
36. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer.
Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C
Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105
[TBL] [Abstract][Full Text] [Related]
37. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
38. Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer.
Greenaway JB; Virtanen C; Osz K; Revay T; Hardy D; Shepherd T; DiMattia G; Petrik J
Oncotarget; 2016 Jul; 7(30):47343-47365. PubMed ID: 27329838
[TBL] [Abstract][Full Text] [Related]
39. Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.
Aust S; Pils S; Polterauer S; Horvat R; Cacsire Castillo-Tong D; Pils D; Dudek G; Schmid B; Speiser P; Reinthaller A; Grimm C
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):518-24. PubMed ID: 23455184
[TBL] [Abstract][Full Text] [Related]
40. Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing.
Zhao Q; Qian Q; Cao D; Yang J; Gui T; Shen K
J Ovarian Res; 2018 Apr; 11(1):31. PubMed ID: 29685168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]